Atezolizumab is approved by FDA for alveolar soft part sarcoma

Share This Post

Dec 2022: Atezolizumab (Tecentriq, Genentech, Inc.) has been approved by the Food and Drug Administration (FDA) for adult and paediatric patients with unresectable or metastatic alveolar soft part sarcoma who are 2 years of age or older (ASPS).

In Study ML39345 (NCT03141684), an open-label, single-arm study involving 49 adult and paediatric patients with metastatic or unresectable ASPS, efficacy was assessed. A ECOG performance status of 2 and histologically or cytologically proven ASPS incurable by surgery were prerequisites for eligibility. Patients were disqualified if they had primary central nervous system (CNS) cancer or symptomatic CNS metastases, clinically significant liver illness, a history of organising pneumonia, pneumonitis, or active pneumonitis on imaging. Pediatric patients got 15 mg/kg (up to a maximum of 1200 mg) intravenously once every 21 days until illness progression or intolerable toxicity. Adult patients received 1200 mg intravenously.

Overall response rate (ORR) and duration of response (DOR), which were determined by an independent review committee using RECIST v1.1, were the primary efficacy outcome measures. (95% CI: 13, 39), ORR was 24%. Sixty-seven percent of the 12 patients who had an objective response had a DOR of six months or longer, and 42 percent had a DOR of twelve months or longer.

The median patient age was 31 years (the range was 12-70); there were 47 adult patients (2% of them were over 65 years old) and 2 paediatric patients (aged 12); 51% of the patients were female; 55% were White; 29% were Black or African Americans; and 10% were Asian.

The most frequent adverse reactions (15%) were musculoskeletal pain (67%), fatigue (55%), rash, cough, nausea, headache, and hypertension (43% each), constipation, dyspnea, dizziness, and haemorrhage (29% each), decreased appetite and arrhythmia (22% each), influenza-like illness, weight loss, and allergic rhinitis anaphylaxis (18% each).

Adult patients should take atezolizumab at a dosage of 840 mg every two weeks, 1200 mg every three weeks, or 1680 mg every four weeks until their disease progresses or the side effects become intolerable. Children 2 years of age and older should get 15 mg/kg (up to 1200 mg) every 3 weeks until the condition progresses or there is intolerable toxicity.


View full prescribing information for Tecentriq.


Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form